Heterotypic responses against nsp12/nsp13 from prior SARS-CoV-2 infection associates with lower subsequent endemic coronavirus incidence.

Autor:	Bean DJ; Department of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA., Monroe J; Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA., Liang YM; Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA., Borberg E; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA., Senussi Y; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA., Swank Z; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA., Chalise S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA., Walt D; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA., Weinberg J; Department of Biostatistics, Boston University School of Public Health, Boston, MA., Sagar M; Department of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.; Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2023 Oct 24. Date of Electronic Publication: 2023 Oct 24.
DOI:	10.1101/2023.10.23.563621
Abstrakt:	Immune responses from prior SARS-CoV-2 infection and COVID-19 vaccination do not prevent re-infections and may not protect against future novel coronaviruses (CoVs). We examined the incidence of and immune differences against human endemic CoVs (eCoV) as a proxy for response against future emerging CoVs. Assessment was among those with known SARS-CoV-2 infection, COVID-19 vaccination but no documented SARS-CoV-2 infection, or neither exposure. Retrospective cohort analyses suggest that prior SARS-CoV-2 infection, but not COVID-19 vaccination alone, protects against subsequent symptomatic eCoV infection. CD8 + T cell responses to the non-structural eCoV proteins, nsp12 and nsp13, were significantly higher in individuals with previous SARS-CoV-2 infection as compared to the other groups. The three groups had similar cellular responses against the eCoV spike and nucleocapsid, and those with prior spike exposure had lower eCoV-directed neutralizing antibodies. Incorporation of non-structural viral antigens in a future pan-CoV vaccine may improve protection against future heterologous CoV infections. Competing Interests: Declaration of Interests The authors have declared that no conflict of interest exists.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu